Azenta, Inc.

Equities

AZTA

US1143401024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 14/09/2024 am IST			5-day change	1st Jan Change
48.52 ^USD	+3.41%		+1.49%	-25.51%

04/09	Azenta Names John Marotta CEO	MT
04/09	Azenta, Inc. Announces Management Changes	CI

Brooks Automation, Inc. Resignation of Timothy S. Mathews as Vice President, Corporate Controller and Principal Accounting Officer

June 12, 2013 at 01:32 am IST

On June 5, 2013, Timothy S. Mathews, the Brooks Automation, Inc.'s Vice President, Corporate Controller and Principal Accounting Officer, tendered his resignation from the Company to be effective on June 21, 2013.

Latest news about Azenta, Inc.

Azenta Names John Marotta CEO	04/09	MT
Azenta, Inc. Announces Management Changes	04/09	CI
Azenta Announces Appointment of John P. Marotta as CEO, Effective September 9, 2024	04/09	CI
Azenta Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Full-Year Guidance Revised	07/08	MT
Tranche Update on Azenta, Inc.'s Equity Buyback Plan announced on November 14, 2022.	07/08	CI
Earnings Flash (AZTA) AZENTA Posts Q3 EPS $0.16	07/08	MT
Earnings Flash (AZTA) AZENTA Posts Q3 Revenue $172.8M, vs. Street Est of $165.6M	07/08	MT
Transcript : Azenta, Inc., Q3 2024 Earnings Call, Aug 06, 2024	07/08
Azenta, Inc. Updates Financial Guidance for the Full Year 2024	07/08	CI
Azenta, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024	07/08	CI
Azenta to Participate in Population Genome Study in Finland	23/07	MT
Finngen Selects Azenta, Inc. to Propel Personalized Medicine for Population Health Study	23/07	CI
Bakkt Names Joe Henderson Chief Accounting Officer	12/07	MT
Transcript : Azenta, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:00 AM	05/06
Azenta Picked to Support Crohn's Disease, Ulcerative Colitis Clinical Research	05/06	MT
Azenta, Inc. Announces Collaboration with the Crohn's & Colitis Foundation to Support Its Crohn's Disease and Ulcerative Colitis Clinical Research	05/06	CI
Needham Adjusts Price Target on Azenta to $69 From $75, Keeps Buy Rating	09/05	MT
Azenta Swings to Fiscal Q2 Adjusted Profit, Revenue Increases; 2024 Guidance Updated; Chief Executive Schwartz to Retire	09/05	MT
Earnings Flash (AZTA) AZENTA Reports Q2 Revenue $159.1M, vs. Street Est of $159.9M	09/05	MT
Earnings Flash (AZTA) AZENTA Posts Q2 EPS $0.05, vs. Street Est of $0.02	09/05	MT
Transcript : Azenta, Inc., Q2 2024 Earnings Call, May 08, 2024	09/05
Tranche Update on Azenta, Inc.'s Equity Buyback Plan announced on November 14, 2022.	09/05	CI
Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024	09/05	CI
Stephen Schwartz to Retire as CEO of Azenta, Inc	09/05	CI
Stephen Schwartz to Retire as Board Director of Azenta, Inc	09/05	CI

Chart Azenta, Inc.

Duration

Period

More charts

Company Profile

Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Companyâs segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

Employees

3,300

Sector

Biotechnology & Medical Research

Calendar

16/09/2024 - GENEWIZ Conference

More about the company